Hindustan Bio Sciences (BOM:532041) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Hindustan Bio Sciences Debt-to-Equity?

Hindustan Bio Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Hindustan Bio Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Hindustan Bio Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hindustan Bio Sciences's Debt-to-Equity or its related term are showing as below:

BOM:532041' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.96 Max: 3.75
Current: 3.75

During the past 13 years, the highest Debt-to-Equity Ratio of Hindustan Bio Sciences was 3.75. The lowest was 0.06. And the median was 0.96.

BOM:532041's Debt-to-Equity is ranked worse than
97.17% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:532041: 3.75

Hindustan Bio Sciences Debt-to-Equity Historical Data

The historical data trend for Hindustan Bio Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hindustan Bio Sciences Debt-to-Equity Chart

Hindustan Bio Sciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

1.56

1.16

1.43

2.75

3.29

Hindustan Bio Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															3.56	N/A	3.29	3.75	N/A

Competitive Comparison of Hindustan Bio Sciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Hindustan Bio Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hindustan Bio Sciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hindustan Bio Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hindustan Bio Sciences's Debt-to-Equity falls into.

Hindustan Bio Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hindustan Bio Sciences's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(13.335	+	11.219)	/	7.466
	=	3.29

Hindustan Bio Sciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Hindustan Bio Sciences (BOM:532041) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hindustan Bio Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hindustan Bio Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hindustan Bio Sciences (BOM:532041) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hindustan Bio Sciences Ltd (BOM:532041) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Road No. 2, Banjara Hills, H.No. 8-2-269/S, Plot No. 31, Sagar Co-Operative Housing Society, Hyderabad, TG, IND, 500034

Website

https://www.hindustanbiosciences.in

Hindustan Bio Sciences Ltd is an India-based company operating in the pharmaceutical and biotechnology sector. It is engaged in the trading of Drugs and Medicines. The company markets a nephrology product, Recombinant Human Erythropoietin, which is useful for the treatment of anemia associated with chronic renal failure. In addition, the firm also manufactures and markets pharmaceutical products in different forms such as tablets, capsules, drops, externals, and syrups. Its other formulations comprise Pantorest, Maxion, Edinil, Aromycin, Livohin and others. Geographically, the group sells its products within India and also exports it to other countries.

Hindustan Bio Sciences (BOM:532041) Headlines

No Headlines